drugset / Trial / NCT00290667
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating older patients with previously untreated B-cell lymphoma.
Timeline
- Start
- 2004-02
- Primary completion
- 2013-12
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Comparator | Rituximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | — | Intravenous |
| Comparator | Pegfilgrastim | Protein / enzyme biologic | — | Subcutaneous |
| Comparator | Prednisone | Other / unclassified | — | Oral |
| Comparator | Vincristine | Small molecule | — | Subcutaneous |